Sep 22, 2020 – MSDG Meeting

Abstract: ProMass is the only fully automated mass spectrum deconvolution software package with versatile integration into ThermoFisher, Waters and SCIEX instrument operating platforms and a wide array of applications.  ProMass can be used to analyze the mass spectra of oligonucleotides, proteins, monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), small molecules and a variety of polymeric materials.  This webinar will focus on the application of ProMass to characterize antibody drug conjugates and oligonucleotides.  One study is the application of ProMass in conjunction with a Waters qTOF mass spectrometer to characterize lysine- and cysteine- antibody drug conjugate standards produced in-house, including automated DAR calculation.  In another study, ProMass HR was partnered with a Thermo Orbitrap to isotopically resolve oligonucleotide standards and a Thermo LTQ XL to develop a high throughput platform for rapid oligonucleotide quality control analysis.

Bio: Robert Schuster holds a B.S. in Biochemistry from Oakland University (2008), an M.S. in Chemistry from Tufts University (2011) and a Ph.D. in Medicinal Chemistry from Purdue University (2016). During his time at Purdue University, Rob worked with Laurie L. Parker and Jean-Christophe Rochet in the study of intracellular tyrosine kinase activation in Parkinson’s disease and Chronic Myeloid Leukemia, using exogenous peptide-based substrates and mass spectrometry (MS) quantitation. This work resulted in a patent on the development of degradation resistant peptide substrates to measure tyrosine kinase activation. As a Senior Research Fellow (Postdoctoral research associate) with Jing Zhang, at the University of Washington School of Medicine, he worked on protein biomarker identification, and the development of MS-based quantitative assays to analyze total protein and PTMs in blood and cerebrospinal fluid of patients diagnosed with Parkinson’s disease. Rob developed chemical derivatization methods to improve the sensitivity of assays measuring abundantly low peptides. Rob joined Novatia as a Senior Scientist in April 2018.

Bio: Kevin received his B.S. in chemistry from the University of Pittsburgh (2016), where he did research under the direction of Dr. Stephen Weber. The bulk of Kevin’s research involved investigating the relationship between column temperature, mobile phase composition, and solute retention using HPLC and various stationary phases. Also during his time at Pitt, he designed and implemented a group research project which utilized GC-MS to determine the relative nicotine and carcinogen content in E-cigarette juices. Kevin joined Novatia in October 2016 as an Associate Research Scientist to provide and improve Novatia’s LC-MS platform services for biomolecules. He was was promoted to Research Scientist in early 2018 and has since expanded his analysis efforts. He also maintains the Novatia website and manages the company’s marketing efforts.